tirzepatide cardiovascular An Observational Study of Outcomes of vs Glucagon-Like Peptide-1 Receptor Agonists Lilly begins dosing in cardiovascular

Retail drugs currently represent 84% of medicine use in the U.S., with only 16% in nonretail settings, and nonretail growth exceeded retail growth in 2025

Circ Heart Fail 13(9):e007485 Krogager ML, Torp-Pedersen C, Mortensen RN et al (2015) Short-term mortality risk of serum potassium levels in acute heart failure following myocardial infarction

Gastrointestinal Adverse Events Of the adverse effects reported during GLP-1 RA clinical trials, gastrointestinal symptoms were the most frequent, with nausea and diarrhea very common, and vomiting, constipation, abdominal pain, and dyspepsia considered to be relatively common [97]

PattiAMGiglioRVAllottaABrunoADi BellaTStoianAPet alEffect of semaglutide on subclinical atherosclerosis and cardiometabolic compensation: a real-world study in patients with type 2 diabetes

More water means lower concentration per unit volume

A key finding of this study is the increased incidence of diarrhea with long-acting and ultra-long-acting GLP-1RAs, particularly semaglutide which a recent meta-analysis similarly found to have a higher diarrhea risk compared to lixisenatide, liraglutide, and exenatide, though lower than tirzepatide (risk ratios 1.661.80 vs